Precision Medicine and Targeted Therapies in Breast Cancer

Ian Greenwalt; Norah Zaza; Shibandri Das; Benjamin D Li

doi:10.1016/j.soc.2019.08.004

Precision Medicine and Targeted Therapies in Breast Cancer

Surg Oncol Clin N Am. 2020 Jan;29(1):51-62. doi: 10.1016/j.soc.2019.08.004. Epub 2019 Oct 29.

Authors

Ian Greenwalt¹, Norah Zaza², Shibandri Das¹, Benjamin D Li³

Affiliations

¹ University Hospitals Cleveland Medical Center, MetroHealth Hospitals, Louis Stokes Veterans Administration Hospital, Case Western Reserve University, Cleveland, OH, USA.
² Case Western Reserve University, Cleveland, OH, USA.
³ MetroHealth System, Case Western Reserve University, Cancer Care Pavilion, Suite C2100, 2500 MetroHealth Drive, Cleveland, OH 44109-1998, USA. Electronic address: bli@metrohealth.org.

PMID: 31757313
DOI: 10.1016/j.soc.2019.08.004

Abstract

Precision medicine and targeted therapies have a long history in the treatment of breast cancer and continue to show promise for further specialized and individualized care for this disease. From the discovery of endocrine and HER2 targeted therapies, to multigene arrays in chemotherapy for more specific patient selection, to radiomics and genetic subtyping, targeted therapies and precision medicine continue to push the management of breast cancer toward more individualized care. This article describes the foundation and future of targeted therapy and precision medicine in breast cancer.

Keywords: Breast cancer; Endocrine therapy; Genomics; HER2; Multigene array; Precision medicine; Radiomics; Targeted therapy.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics*
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Female
Humans
Molecular Targeted Therapy / methods*
Pharmacogenetics / methods*
Precision Medicine / methods
Precision Medicine / trends*

Substances

Antineoplastic Agents
Biomarkers, Tumor